<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03966079</url>
  </required_header>
  <id_info>
    <org_study_id>BeijingTCGH</org_study_id>
    <nct_id>NCT03966079</nct_id>
  </id_info>
  <brief_title>Thrombolysis Endovascular Treatment of Pulmonary Embolism</brief_title>
  <acronym>STEP</acronym>
  <official_title>Single-dose rtPA Thrombolysis Endovascular Treatment of Pulmonary Embolism With Right Ventricular Dysfunction:a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tsinghua Chang Gung Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tsinghua Chang Gung Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of endovascular thrombolysis of pulmonary embolism with
      right ventricular dysfunction with single-dose rtPA
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients with right ventricular dysfunction who are diagnosed by CT pulmonary angiography
      will receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through
      the in this study. The Change of RV to LV Diameter Ratio,Rate of death,rate of major
      bleeding,pulmonary embolism recurrence at 1month will be reviewed to assess the efficacy and
      safety.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective Single Group Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of RV to LV Diameter Ratio</measure>
    <time_frame>baseline and 30days after baseline</time_frame>
    <description>Determine whether single-dose rtpa catheter-directed thrombolysis decrease the ratio of right ventricular (RV)-to-left ventricular (LV) diameter within 1month in patients with right ventricular dysfunction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of death</measure>
    <time_frame>30days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of major Bleeding</measure>
    <time_frame>30days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary embolism recurrence</measure>
    <time_frame>30days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pulmonary Embolism</condition>
  <condition>Acute Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant tissue plasminogen activator</intervention_name>
    <description>Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter</description>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>rtPA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CT evidence of proximal PE

          -  Age ≥ 18 years

          -  Pulmonary embolism symptom duration ≤14 days

          -  Massive PE (syncope, systemic arterial hypotension, cardiogenic shock, or resuscitated
             cardiac arrest) OR Submassive PE (RV diameter-to-LV diameter ≥ 0.9 on
             contrast-enhanced chest CT)

        Exclusion Criteria:

          -  Age &lt;18 years

          -  PE symptom duration &gt;14 days

          -  Stroke or transient ischemic attack (TIA), head trauma, or other active intracranial
             or intraspinal disease within one year

          -  Recent (within one month) or active bleeding from a major organ

          -  Pregnancy

          -  Chronic pulmonary hypertension or severe chronic obstructive pulmonary disease

          -  Administration of thrombolytic agents within the previous 3 days

          -  Life expectancy &lt; 30 days

          -  Any other condition that the investigator feels would place the patient at increased
             risk if the investigational therapy is initiated

          -  Inability to follow protocol requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wu weiwei, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Director of department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Tsinghua Chang Gung Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>102218</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 20, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>July 5, 2020</last_update_submitted>
  <last_update_submitted_qc>July 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Pulmonary Embolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

